Fig. 1 (abstract P136a).From: 16th European Headache Congress 2022 meeting abstractsZavegepant Nasal Spray versus Placebo in the Acute Treatment of Migraine: Summary of Results on Coprimary and Secondary Efficacy Endpoints.*Back to article page